European Commission launches bioeconomy funding push and backs food biotech scale-up

The European Commission and the Circular Bio-based Europe Joint Undertaking have brought together European banks, national promotional institutions, venture capital funds and institutional investors to create the Bioeconomy Investment Deployment Group to help Europe’s sustainable industries secure the funding they need to grow. The group aims to reduce financial risks for investors, create clear funding standards, and bring together public and private money, while the Commission’s investment proposals include a €350 million funding package to accelerate food and biotech innovation.

Despite already supporting 17 million jobs and generating up to €2.7 trillion in economic value, many innovative bio-based projects struggle to secure financing at critical stages, such as moving from small-scale testing to full industrial production. A recent study confirmed that the sector suffers from structural financing gaps at the most capital-intensive stages of the innovation curve: pilot to demonstration, and demonstration to first-of-a-kind industrial deployment and commercialisation.

This week’s event in Brussels formally launched the process leading to the Deployment Group’s first plenary in June 2026 and the submission of its 2026–2029 work plan to the CBE JU Governing Board. Instead of just talking about solutions, the group will focus on four key areas that match the funding process:

• Designing better financing instruments, including blended-finance architectures, risk-sharing facilities and guarantee instruments tailored to long-duration bio-based projects.
• Building a bankable project pipeline through a common understanding of project bankability aspects, shared due diligence standards, and governance for a database of investment-ready projects.
• Improving transparency by monitoring and reporting, including a digital eligibility checker aligned with existing sustainability and taxonomy frameworks, together with methodologies for tracking capital flows into the sector.
• Connecting bio-based scale-ups with financial institutions and corporates matched by ticket size, risk appetite and sectoral focus.

The discussions highlighted three priorities that will shape the work plan: standardised contracts and criteria, long-term patient funding, and more communication on Europe’s bioeconomy plans as emerging from the EU Bioeconomy Strategy and the forthcoming Biotech Act II. The group already includes the European Investment Bank Group, national promotional banks, and specialist venture and growth-equity funds with mandates in industrial decarbonisation, but participation from large commercial banks, pension funds and insurance companies remains limited.

The Commission’s broader proposals aim to accelerate innovation in sustainable food production as part of the Strategy for European Life Sciences. In mid-2025, the Commission announced a €350 million funding package, partly channelled through Horizon Europe, to enable advanced and precision fermentation technologies to produce sustainable food ingredients, with around €150 million allocated in 2025 and a further €200 million earmarked for 2026–2027.

The funding targets the scaling of fermentation processes, support for startups and SMEs commercialising research, and the establishment of public-private collaboration platforms. The proposals seek to address infrastructure gaps, high demonstration-facility costs, regulatory complexity, lengthy approval processes under the EU’s Novel Foods framework, market fragmentation across member states, and limited growth-stage venture capital.

The Commission has also proposed boosting access to funding to help EU biotech companies grow and scale up. In cooperation with the European Investment Bank, it will run a health biotech pilot in 2026 and 2027 to complement the EIB’s biotech initiative that will mobilize up to EUR 10 billion in investment in the sector.